Quest Diagnostics Stock News

Morgan Stanley lifted its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 38.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 2,056,324 shares of the medical research companys stock after buying an additional 567,239 shares during the period. Morgan Stanleys holdings in Quest Diagnostics were worth $271,372,000 as of its most recent filing with the []

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

Quest Diagnostics Incorporated with ticker code (DGX) now have 15 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 181 and 150 calculating the mean target price we have 162. With the stocks previous close at 160.06 this is indicating there is a potential upside of 1.2%. The day 50 moving average is 147.57 while the 200 day moving average is 139.62. The company has a market capitalisation of $20,028m. You can visit the company''s website by visiting: https://www.questdiagnostics.com [stock_market_widget type="chart" symbol="DGX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Quest Diagnostics Incorporated (NYSE:DGX) Analysts at KeyCorp lifted their FY2021 EPS estimates for shares of Quest Diagnostics in a report issued on Sunday, December 12th. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings of $14.17 per share for the year, up from their previous forecast of $13.90. KeyCorp []

Quest Diagnostics (NYSE:DGX) had its price target hoisted by KeyCorp from $168.00 to $170.00 in a research report released on Monday, Price Targets.com reports. KeyCorp currently has an overweight rating on the medical research company’s stock. Other equities analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares […]

Janney Montgomery Scott LLC grew its position in Quest Diagnostics Incorporated (NYSE:DGX) by 5.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 75,681 shares of the medical research companys stock after acquiring an additional 3,856 shares during the period. Janney Montgomery Scott LLC owned 0.06% of Quest []

At this point in the novel coronavirus pandemic, were still learning about the long-term effects of the virus, and how those risks might vary based on age, socioeconomic class, region, and so on. Whether youve lived with COVID-19 or not, though, its certainly possible the pandemic has still affected your physical and mental health. According to a recent study from the Cleveland Clinic, there has been a serious increase in blood pressure during the pandemic, especially among women. The study, which was published in the journal Circulation on Monday, Dec. 6, included people from 50 states plus Washington, D.C., with more than 460,000 people surveyed. The data came from a wellness program put on by several employers through Quest Diagnostics. The study included both employees and their spouses or partners. The average age of study participants was 45 years old and slightly more than half of the participants were women. Frustratingly, the data doesnt include information on race and ethnicity.

Kestra Advisory Services LLC trimmed its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,730 shares of the medical research companys stock after selling 336 shares during the quarter. Kestra Advisory []

@MUSZYNSKIBP BRISTOL -- A New Britain woman is set to appear before a judge next month on charges she assaulted a health care worker in Bristol who noticed the urine sample she provided for a drug test was not the right temperature. Wilma Smith, 27, faces charges of second-degree breach of peace and assault on public safety, emergency medical, public transit or health care personnel. She is free without having to post bond and is scheduled to appear in New Britain Superior Court on Jan. 26. According to the arrest warrant, police were called to Quest Diagnostics, located at 935 Farmington Ave., on Sept. 16, around 2:40 p.m., on the report of an assault. Officers who responded spoke to a phlebotomist who said Smith had come in to take a drug test for a job at a local car dealership, the warrant said. After Smith returned from the bathroom with a urine sample, the employee said, he took the required temperature reading of the sample before sealing the sample and signing the paperwork. According to the phlebotomist, he told Smith that the temperature was reading too low for a standard urine sample, the warrant said.

The global Treatment for H Pylori market size is projected to reach US$ 249.4 million by 2027, at a CAGR of 8.3% during 2021-2027. Infections with Helicobacter pylori are particularly common in underdeveloped countries. The spread of these illnesses can

Everence Capital Management Inc. acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,720 shares of the medical research companys stock, valued at approximately $395,000. Other institutional investors and hedge funds have also added to []

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.

Coho Partners Ltd. lowered its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 14.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 138,189 shares of the medical research companys stock after selling 24,214 shares during the quarter. Coho Partners Ltd. owned about 0.11% []

Raymond James Trust N.A. lessened its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 11.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,287 shares of the medical research companys stock after selling 413 shares during the quarter. Raymond James []